Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.12.2013 | editorial | Ausgabe 4/2013

memo - Magazine of European Medical Oncology 4/2013

Antibody–drug conjugates (ADCs)—new targeted therapies

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 4/2013
Autor:
MD, PhD Dr. Georgios Papakonstantinou

Abstract

The promise of all targeted therapies is the specific induction of cytotoxicity in malignant cells without adversely affecting normal tissues. Antibody–drug conjugates (ADCs) consist of a monoclonal antibody chemically linked to an anticancer agent, and are a niche class of drugs that raise great expectations, particularly as oncology drugs. Brentuximab vedotin and trastuzumab emtansine, both recently US Food and Drug Administration approved, open a promising new area in the therapy of hematologic malignancies and solid tumors. Further improvement of bioengineering and development of preclinical and clinical data are the challenges for the next generation of ADCs.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2013

memo - Magazine of European Medical Oncology 4/2013 Zur Ausgabe